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Localised autonomic failure due to bot­
ulinum  toxin injection
I read with great interest Mann’s report of a 
patient receiving botulinum toxin injections 
for spasmodic torticollis who developed 
sialectasis and swelling of the parotid glands 
after each set of injections.1 Local diffusion 
of the toxin and paralysis of the smooth 
muscle of the salivary ducts was proposed 
as a possible underlying mechanism.1
The inhibitory action of botulinum toxin 
is not confined to the neuromuscular junc­
tion. All the autonomic cholinergic fibres 
including the major secretomotor fibres to 
salivary glands are similarly blocked. Local 
diffusion and “chemodenervation” of the 
parotid glands leading to reduction of sali­
vary flow and the development of chronic 
recurrent parotitis seems to be a more likely 
explanation for this patient’s symptoms. 
Dickson and Shevky in 1923 showed that 
tympanic nerve-induced salivary flow was 
blocked by the toxin in cats.2 In botulism, 
dry mouth is a common symptom, occur­
ring in about 93% of patients.3 Dry mouth 
has also been reported in some 30% of 
patients after cervical injections for spas­
modic torticollis.“1 Paradoxically, excessive 
salivation has long been known to occur in 
botulism.2 A similar paradoxical effect on 
lacrimal glands producing watering of the 
eyes has been reported in patients receiving 
periorbital injections for blepharospasm or 
hemifacial spasm.5 This paradoxical effect 
of the toxin on the “neuroglandular junc­
tion” remains unexplained. Increased saliva 
production may partly be responsible for 
parotid swelling after botulinum toxin injec­
tions in the patient reported.
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M ann replies:
J am grateful to Dr Bushara for his interest 
and comments. I too had considered other 
potential mechanisms for the salivary gland 
swelling but favoured duct paralysis for a 
number of reasons.
The patient clearly still secreted saliva as 
she was able to empty the glands “manu­
ally” with massage. Chrpnic infection was 
rejected on the basis of negative growth
from swabs and absent response to broad 
spectrum antibiotics.
The concept of paradoxical hypersecre­
tion is intriguing but one would not expect 
a dry mouth to result. Duct paralysis best 
explains the combination of symptoms and 
signs in this patient.
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Immunoglobulin treatment in human 
and experimental epilepsy
The paper of van Engelen et a l 1 mentions 
some positive effects o f intravenous 
immunoglobulins (IVTg) in the treatment of 
refractory epilepsy. N o  reference about our 
experience in that field is mentioned, how­
ever, in the medical literature reviewed by 
Van Engelen et al.1
In 1983, we successfully treated with 
IVTg a patient with severe Lennox-Gastaut 
syndrome who still remains seizure free.2 
Thereafter in a first open study, 20 patients 
with Lennox-Gastaut syndrome and partial 
epilepsy were infused with IVIg,34 This 
treatment gave excellent results in two 
patients, who were seizure free for months 
but relapsed afterwards although their 
seizures were less severe than before the 
infusions. In this open study, 15 patients 
have partially improved including eight with 
a pronounced decrease of seizures* It was 
concluded that IVIg treatment may be very 
helpful not only in West and Lennox- 
Gastaut syndrome s, but als o in parda I 
epilepsy, including Rasmussen’s syndrome.5
At that timej however all studies pub­
lished about IVIg in refractory epilepsy were 
open designs—with the exception of that of 
Ilium et a lf which was a single blind, cross 
over trial—with controversial schedules and 
doses. Indeed the patients received from 
two to more than 10 infusions with doses 
ranging from 100 mg to 1 g/kg/perfusion 
and no relation was assessed between dose 
or schedule of IVIg and clinical responsive­
ness. An overview o f the medical literature 
involving about 200 epileptic patients 
treated with IVIg showed a positive 
response to this treatment in around 50% of 
the patients,7 Taking that into account, in 
1989 we initiated the first double blind 
study to establish a dose of IVIg for treat­
ment of epilepsy.7 Sixty one patients were 
randomly assigned to receive either IVIg (n 
= 43) or a placebo (n = 18) at three differ­
ent doses (100, 250, or 400 mg/kg/infu­
sion). No dose effect was found (P = 0*31). 
The data for the whole study population 
showed an improvement in 52*5 % of 
patients treated with IVIg (in accordance 
with previously reported open studies), 
compared with 27-8% in the placebo group; 
this positive trend was not significant (P = 
0*09). When only the patients with partial 
epilepsy were assessed, a significant differ­
ence in favour o f the IVIg treatment was 
found (P = Û-04) and this was confirmed in 
the subgroup o f partial epilepsy with secon­
darily generalised seizures (n = 30) regard­
less of the dose (P = 0’04). Two patients 
became seizure free. One with Lennox- 
Gastaut syndrome needs no further anti­
convulsant medication. The other, who had
partial epilepsy, relapsed but is still better 
than before the IVTg.
The mechanisms of action are unknown. 
We found some relation between a lower 
serum IgA level and a better clinical 
response in the first study,4 but could not 
confirm this correlation in the double blind 
study7 although we noted a trend in favour 
of a lower serum IgA. Infusions of IVIg in 
refractory epilepsy are well tolerated but the 
major problems related to this treatment 
concern its cost and the hazards of trans­
mission of infectious diseases linked to 
blood derivatives. Immunoglobulins may be 
considered safe however, as their manufac­
turing procedures are known to inactivate 
human pathogenic viruses such as hepatitis 
A, B and C, and HIV I and II.
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Van Engelen et al reply;
We thank van Rijckevorsel and Delire for 
their interest in our paper on immunoglob­
ulin treatment in human and experimental 
epilepsy.1 Their point was that we did not 
mention their experience in that field. Our 
paper was an overview on some aspects of 
immunoglobulin effects in human and 
experimental epilepsies; it was not a review 
of the medical literature on immunoglobu­
lin treatment in human epilepsies, We wrote 
a 1993 review on current immunoglobulin 
treatment in human epilepsies,2 and there 
we recognised their contribution in the field 
by citing three papers published by van
Rijckevorsel and colleagues.
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